Sugi Predict

Sugi Predict / Compounds / SCHEMBL8296756

SCHEMBL8296756

SCHEMBL8296756

CCOC(=O)c1cc2ccccc2n1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.63
▸ TSHR P16473 1/20 0.63
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ NOD2 Q9HC29 6/20 0.57
▸ NOD1 Q9Y239 6/20 0.57
▸ MAPT P10636 2/20 0.56
▸ GAA P10253 1/20 0.56
▸ KDM4E B2RXH2 2/20 0.55
▸ CRHBP P24387 1/20 0.55
▸ CRHR2 Q13324 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ RECQL P46063 1/20 0.51
▸ F10 P00742 2/20 0.51
▸ PLA2G10 O15496 3/20 0.49
▸ SIRT2 Q8IXJ6 1/20 0.48
▸ SIRT1 Q96EB6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11004197 0.86 NOD2 (0.50) ALDH1A1TSHRMEN1KMT2ANOD2
SCHEMBL6019148 0.85 ALDH1A1 (0.50) ALDH1A1TSHRMEN1KMT2ANOD2
SCHEMBL6298947 0.85 NOD2 (0.68) ALDH1A1TSHRMEN1KMT2ANOD2
SCHEMBL5265086 0.85 NOD2 (0.49) ALDH1A1TSHRMEN1KMT2ANOD2
SCHEMBL22760557 0.84 MAPT (0.51) ALDH1A1TSHRMEN1KMT2ANOD2
SCHEMBL15466939 0.84 ALDH1A1 (0.69) ALDH1A1TSHRKMT2AMAPTKDM4E
SCHEMBL9098494 0.83 LMNA (0.57) ALDH1A1TSHRMEN1KMT2ANOD2
SCHEMBL27782460 0.83 NOD2 (0.55) ALDH1A1TSHRMEN1KMT2ANOD2
SCHEMBL9268943 0.82 LMNA (0.53) ALDH1A1TSHRMEN1KMT2ANOD2
SCHEMBL6019391 0.81 NOD2 (0.55) ALDH1A1MEN1KMT2ANOD2NOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102659663-A Preparation method of 5-chloro-3-phenylindole-2-carbonyl acid ethyl ester SHANGHAI INST TECHNOLOGY 2012-09-12 — — CN claimed
CN-109748840-B Synthetic method of 2-substituted indole derivative 中国医学科学院药物研究所 2021-12-07 — — CN disclosed
US-10941162-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2021-03-09 — — US disclosed
US-10919914-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2021-02-16 — — US disclosed
US-20190330240-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2019-10-31 — — US disclosed
US-20190135833-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2019-05-09 — — US disclosed
US-10253047-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2019-04-09 — — US disclosed
US-20170369511-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2017-12-28 — — US disclosed
US-9708348-B2 Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-07-18 — — US disclosed
US-9708348-B2 Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-07-18 — — US disclosed
US-20160122365-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2016-05-05 — — US disclosed
EP-0553218-B1 INDOLE DERIVATIVES RECKITT & COLMANN PROD LTD (GB) 1999-06-16 — — EP disclosed
US-5385919-A Antidiabetic agents RECKITT & COLMAN PRODUCTS LIMITED (GB) 1995-01-31 — — US disclosed
EP-0553218-A1 INDOLE DERIVATIVES RECKITT & COLMAN PRODUCTS LIMITED (GB) 1993-08-04 — — EP disclosed
WO-1992006972-A1 INDOLE DERIVATIVES RECKITT & COLMAN PRODUCTS LIMITED (GB) 1992-04-30 — — WO disclosed
US-4912125-A 2,3-dihydro-2-(4,5-dihydroimidazol-2-yl)-indoles for reducing intraocular pressure CIBA-GEIGY CORPORATION (US) 1990-03-27 — — US disclosed
US-4908376-A 2,3-dihydro-2-(4,5-dihydroimidazol-2-yl)-indoles in composition form for reducing intraocular pressure CIBA-GEIGY CORPORATION (US) 1990-03-13 — — US disclosed
CN-1005974-B Process for preparing acid indole compounds 沃纳·兰伯特公司 1989-12-06 — — CN disclosed
US-4659731-A 2-(4,5-Dihydro-1H-imidazol-2-yl)-2,3-dihydroindole derivatives and their application as α2 receptor antagonist or α1 receptor agonists SYNTHELABO (FR) 1987-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919914-B2 Heterocyclic compounds and uses thereof PIK3CA, PIK3CD, PIK3CB ALDH1A1 3154/4885TSHR 4224/4885MEN1 1386/4885
US-20170369511-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB ALDH1A1 3154/4885TSHR 4224/4885MEN1 1386/4885
US-20190135833-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB ALDH1A1 3154/4885TSHR 4224/4885MEN1 1386/4885
US-20160122365-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB ALDH1A1 3154/4885TSHR 4224/4885MEN1 1386/4885
US-10941162-B2 Heterocyclic compounds and uses thereof PIK3CA, PIK3CD, PIK3CB ALDH1A1 2938/4885TSHR 3933/4885MEN1 2006/4885
US-20190330240-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB ALDH1A1 3154/4885TSHR 4224/4885MEN1 1386/4885
US-10253047-B2 Heterocyclic compounds and uses thereof PIK3CA, PIK3CD, PIK3CB ALDH1A1 3746/4885TSHR 3940/4885MEN1 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.